The Long-Standing National Frameworks

Part of Regulatory Affairs and the Jurisdiction Map: Jurisdictions with Their Own Instruments.

About 5 minutes. Free, in your language, no account needed.

Why this matters

Several countries had functioning clinical trial regulation before international harmonization, and they kept their own instruments. These frameworks are substantively aligned with the global baseline without being identical to it, and the differences are specific rather than sweeping.

Knowing where a country's framework is its own rather than an adoption tells you where to look for divergence. It is a small number of places, and they are consistent.

Japan

Japan's framework is set out in the Ministerial Ordinance on Good Clinical Practice, Ordinance 28, under the Ministry of Health, Labour and Welfare, with the Pharmaceuticals and Medical Devices Agency conducting the review. It is commonly referred to as J-GCP.

J-GCP is aligned with ICH GCP, which is unsurprising given Japan's role as a founding participant in the harmonization effort. What distinguishes it operationally is the density of its documentation expectations and the formality of the institutional review structure, where the review board sits within the medical institution and the head of that institution holds a defined role in the approval chain that has no direct counterpart elsewhere.

The practical consequence for a sponsor is that a document set assembled for a Western study frequently needs restructuring rather than translating, and that the institutional approval path has a step teams do not anticipate.

Canada

Canada regulates clinical trials under the Food and Drug Regulations, Division 5, administered by Health Canada. The framework incorporates good clinical practice expectations and adds Canadian requirements, notably around the qualified investigator and the requirement for a Canadian regulatory presence.

The default review period is defined, and the framework distinguishes between amendments requiring authorization and notifications that do not. Getting that classification right is the everyday work of Canadian regulatory maintenance.

The United Kingdom

The United Kingdom applies its own framework through the Medicines and Healthcare products Regulatory Agency, having left the European Union's coordinated procedure. CRLN's register records the United Kingdom as a distinct governing regime for this reason.

The practical point for a sponsor running across Europe is that the United Kingdom is now a separate submission, on its own timeline, outside the single application covering the member states. A team that mentally files the United Kingdom under "Europe" will plan one submission where two are required.

The United Kingdom also operates a combined review arrangement bringing the regulatory and ethics reviews together, which is a genuine simplification and a difference from most jurisdictions.

Australia

Australia is administered by the Therapeutic Goods Administration with the National Health and Medical Research Council's ethical framework. Its distinguishing feature is the notification scheme, under which many trials proceed on the basis of a notification supported by ethics approval rather than a full regulatory assessment, with a separate approval route for trials that do not qualify.

This inverts the usual sequence. The human research ethics committee's approval carries the substantive weight, and the regulatory step is lighter than a sponsor accustomed to a regulator-first framework expects. Teams routinely over-prepare the regulatory submission and under-prepare the ethics submission, which is the wrong way round.

Switzerland

Switzerland is recorded as an ICH member jurisdiction with its own national framework, sitting outside the European Union's coordinated procedure despite being surrounded by it. As with the United Kingdom, the planning error is geographic: Switzerland is a separate submission.

In practice

A sponsor plans a study across Europe, and the study team's map shows twenty nine countries in one block.

The regulatory lead splits it into three. Twenty seven member states go through a single coordinated application under the European Union's Regulation. The United Kingdom is a separate submission under its own framework with its own timeline and its own combined review. Switzerland is a third separate submission.

Three submissions, three timelines, three sets of questions. The study team's plan assumed one, and the difference is not weeks of effort but the entire shape of the start-up schedule and the headcount required to run it.

This is the most common single planning error in European regulatory work, and it is purely a consequence of thinking geographically rather than in terms of governing instruments.

What this looks like when it goes wrong

A sponsor treats Japan as a translation exercise. The global dossier is translated, the protocol is translated, and the submission is made.

The framework's documentation expectations and the institutional approval structure are not satisfied by the translated Western document set, and the submission attracts an extended series of questions. What was planned as a three month start-up becomes eight.

Nothing was mistranslated. The error was assuming that a framework aligned with ICH GCP would accept a document set built for a different framework aligned with ICH GCP. Alignment at the level of principle does not mean interchangeability at the level of dossier.

Key takeaways